Form 4 for XERS Xeris Biopharma Holdings, Inc.
Accepted 2023-11-17 00:00:00 ET · period of report 2023-11-17 · accession 0001867096-23-000145 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-11-17 | 2023-11-17 | XERS | Shannon John Patrick Jr | See Remarks | P - Purchase | $1.64 | +30.8K | 1.41M | +2% | +$50.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-17 | P | A | 30,769 | $1.64 | 1,408,575 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.6250 to $1.6400, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. |